This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Star Scientific's Rock Creek Subsidiary Enrolls First Alzheimer's Study Patient At Roskamp Institute

GLEN ALLEN, Va., Aug. 23, 2012 /PRNewswire/ --  Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary Rock Creek Pharmaceuticals Inc., announced today that the Alzheimer's study of the company's dietary supplement Anatabloc ®  has screened and enrolled its first patient. 

(Logo: )

The Alzheimer's study, entitled, " A Three Month, Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability and Potential Effect of the Dietary Supplement Anatabine in Subjects with Alzheimer's Disease," has its origins in basic research conducted at the Roskamp Institute ( Sarasota, FL) and from case reports of beneficial effects of the company's dietary supplement Anatabloc® in individuals using the nutritional supplement under their physician's care.

The anatabine citrate used in Anatabloc® has been shown to be effective in lowering amyloid levels and other markers of inflammation in both tissue studies conducted in a laboratory setting and in animal research.  In addition, Anatabloc® has been reported by others to be a useful nutritional supplement in Alzheimer's disease. The company received a patent for the synthesis of anatabine in June 2012, and a patent is pending for the Anatabloc® formulation. Preparations for the Alzheimer's study were extensive and included pharmacokinetic and tolerability studies, a review of the safety of Anatabloc® in other clinical trials that had the same usage level as in the Alzheimer's study, and a review of post-marketing reports for the Anatabloc® product itself.

The study will enroll 120 subjects with mild to moderate Alzheimer's disease and randomize these patients, who will then receive, on a blinded basis, either the active Anatabloc® supplement or a placebo. The subjects then will be monitored throughout the course of their assigned treatment to evaluate tolerability, safety, blood levels of inflammatory markers, and functional status. The intent of the study is to determine the safety of Anatabloc® in this population, and determine if there is evidence of a reduction in inflammatory markers or a change in functional status.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs